Tag - Tocagen

Tocagen’s (NASDAQ:TOCA) Phase 3 Toca 5 clinical trial, evaluating Toca 511 and Toca FC, in patients with recurrent high grade glioma, undergoing resection, missed the primary endpoint of overall survival, compared with...